Suppr超能文献

[全身照射:当前适应症]

[Total body irradiation: current indications].

作者信息

Giraud P, Danhier S, Dubray B, Cosset J M

机构信息

Département d'oncologie-radiothérapie, Institut Curie, Paris, France.

出版信息

Cancer Radiother. 1998 May-Jun;2(3):245-51. doi: 10.1016/s1278-3218(98)80001-2.

Abstract

The choice of dose and fractionation for total body irradiation is made difficult by the large number of considerations to be taken into account. The outcome of bone marrow transplantation after total body irradiation can be understood in terms of tumour cell killing, engraftment, and normal tissue damage, each of these endpoints being influenced by irradiation-, disease-, transplant-, and patient-related factors. Interpretation of clinical data is further hampered by the overwhelming influence of logistic constraints, the small numbers of randomised studies, and the concomitant variations in total dose and fraction size or dose rate. So far, three cautious conclusions can be drawn in order to tentatively adapt the total body irradiation schedule to clinically-relevant situations. Firstly, the organs at risk for normal tissue damage (lung, liver, lens, kidney) are protected by delivering small doses per fraction at low dose rate. This suggests that, when toxicity is at stake (e.g., in children), fractionated irradiation should be preferred, provided that interfraction intervals are long enough. Secondly, fractionated irradiation should be avoided in case of T-cell depleted transplant, given the high risk of graft rejection in this setting. An alternative would be to increase total (or fractional) dose of fractionated total body irradiation, but this approach is likely to induce more normal tissue toxicity. Thirdly, clinical data have shown higher relapse rates in chronic myeloid leukaemia after fractionated or low dose rate total body irradiation, suggesting that fractionated irradiation should not be recommended, unless total (or fractional) dose is increased. Total body irradiation-containing regimens, primarily cyclophosphamide/total body irradiation, are either equivalent to or better than the chemotherapy-only regimens, primarily busulfan/cyclophosphamide. Busulfan/cyclophosphamide certainly represents a reasonable alternative, especially in patients who may not be eligible for total body irradiation because of prior irradiation to critical organs.

摘要

全身照射剂量和分割方式的选择因需考虑的因素众多而变得困难。全身照射后骨髓移植的结果可从肿瘤细胞杀灭、植入和正常组织损伤等方面来理解,这些终点中的每一个都受到照射、疾病、移植和患者相关因素的影响。后勤限制的压倒性影响、随机研究数量少以及总剂量、分割大小或剂量率的伴随变化进一步阻碍了临床数据的解读。到目前为止,可以得出三个谨慎的结论,以便初步使全身照射方案适应临床相关情况。首先,通过低剂量率每次分割给予小剂量来保护有正常组织损伤风险的器官(肺、肝、晶状体、肾)。这表明,当涉及毒性问题时(例如在儿童中),如果分割间隔足够长,应优先选择分次照射。其次,在T细胞去除的移植情况下应避免分次照射,因为在这种情况下移植排斥风险很高。一种替代方法是增加分次全身照射的总(或分次)剂量,但这种方法可能会诱发更多的正常组织毒性。第三,临床数据显示,分次或低剂量率全身照射后慢性髓性白血病的复发率较高,这表明除非增加总(或分次)剂量,否则不建议采用分次照射。含全身照射的方案,主要是环磷酰胺/全身照射,等同于或优于仅化疗方案,主要是白消安/环磷酰胺。白消安/环磷酰胺无疑是一种合理的替代方案,特别是对于那些由于先前对关键器官进行照射而可能不符合全身照射条件的患者。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验